



(43) International Publication Date
18 April 2013 (18.04.2013)

(10) International Publication Number
WO 2013/055888 A3

- (51) **International Patent Classification:**
C12N 9/26 (2006.01) *A61K 38/47* (2006.01)
C12N 5/07 (2010.01)
- (21) **International Application Number:**
PCT/US2012/059708
- (22) **International Filing Date:**
11 October 2012 (11.10.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/546,248 12 October 2011 (12.10.2011) US
- (71) **Applicant:** SYNAGEVA BIOPHARMA CORP.
[US/US]; 128 Spring Street, Suite 520, Lexington, MA
02421 (US).
- (72) **Inventors:** QUINN, Anthony; 107 Manet Road, Chestnut
Hill, MA 02467 (US). LEAVITT, Markley, C.; 1140
Latham Drive, Watkinsville, GA 30677 (US). ZHINAN,
Xia; 29 Burke Lane, Wellesley, MA 02481 (US).
RUTKOWSKI, Joseph, Victor; Synageva Biopharma
Corp., 128 Spring St., Suite 520, Lexington, MA 02421
(US).
- (74) **Agents:** ZACHARAKIS, Maria, Laccotripe et al.; Mc-
Carter & English, LLP, 265 Franklin Street, Boston, MA
02110 (US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

- (88) **Date of publication of the international search report:**
13 June 2013

(54) **Title:** RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF

(57) **Abstract:** The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.



WO 2013/055888 A3